Sponsor

Duchenne Muscular Dystrophy Market Hits $800M in 2023, Set for 7% Growth Ahead

0
3K

According to a new report by UnivDatos Market Insights, the Duchenne Muscular Dystrophy Market reached USD 800 million in 2023 and will grow at a CAGR of ~7% during the year 2024-32F. This is mainly because expanding treatment options will give patients access to a broader range of treatment options, enabling growth and penetration in the Duchenne Muscular Dystrophy industry as more therapies receive regulatory approval. For instance, on March 21, 2024, the U.S. Food and Drug Administration approved Duvyzat (givinostat) oral medication for treating Duchenne Muscular Dystrophy (DMD) in patients six and older. Duvyzat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. This expansion will enhance personalized care approaches, allowing for better disease management based on individual patient needs.

For More Detailed Analysis in PDF Format, Visit- https://univdatos.com/reports/duchenne-muscular-dystrophy-market?popup=report-enquiry

The ability to tailor treatments to individual genetic profiles and specific disease manifestations enhances patient outcomes and drives market demand. Some of the key developments influencing the Duchenne Muscular Dystrophy market include:

·       On March 28, 2024, Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) announced the launch of a groundbreaking model-based Clinical Trial Simulator (CTS) specifically designed to improve the design of efficacy studies for potential therapies for Duchenne muscular dystrophy (DMD). This pioneering Drug Development Tool is set to positively impact the medical research community by significantly optimizing clinical trial design.

·       On January 5, 2023, Sarepta Therapeutics announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).

·       On September 30, 2022, Solid Biosciences Inc., a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), announced the closing of its acquisition of AavantiBio, Inc., a privately held gene therapy company focused on transforming the lives of patients with Friedreich’s ataxia and rare cardiomyopathies. The acquisition included its pipeline assets and net cash.

The regulatory framework's focus on personalized medicine has led to the approval of treatments tailored to individual needs and desired outcomes, enhancing patient satisfaction and driving market demand. Some of the most approved treatments for Duchenne Muscular Dystrophy include:

The treatment of Duchenne muscular dystrophy has included significant non-steroidal advances that offer new hope for managing the disease. Among these, Duvyzat (givinostat) stands out as a noteworthy development. Approved by the FDA in March 2024, Duvyzat is a non-steroidal histone deacetylase (HDAC) inhibitor that has demonstrated efficacy in reducing muscle deterioration across all genetic forms of Duchenne muscular dystrophy.

·       On June 22, 2023, Sarepta Therapeutics announced U.S. Food and Drug Administration (FDA) accelerated approval of ELEVIDYS, an adeno-associated virus-based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.

Explore the Comprehensive Research Overview - https://univdatos.com/reports/duchenne-muscular-dystrophy-market

Related Reports:

Polymethyl Methacrylate (PMMA) Market

Ammonia (NH3) Gas Sensor Market

Carbon Nanotubes (CNT) Market

Adeno-Associated Virus Gene Therapy Market

Non-Surgical Skin Tightening Market

Conclusion

In conclusion, the Duchenne Muscular Dystrophy (DMD) market is poised for substantial growth, fueled by increasing prevalence, innovative therapies, and a supportive regulatory landscape. With a projected CAGR of ~7% from 2024 to 2032, the market registered USD 800 million in 2023. The market is witnessing significant advancements, such as the approval of Duvyzat and ELEVIDYS, marking a shift towards personalized medicine. Moreover, initiatives like the launch of the Clinical Trial Simulator and strategic agreements between companies further indicate a promising future for DMD treatment development and patient care.

Contact Us:

UnivDatos Market Insights

Contact Number - +19787330253

Email - contact@univdatos.com 

Website - www.univdatos.com

Linkedin- https://www.linkedin.com/company/univ-datos-market-insight/mycompany/

Sponsor
Sponsor
Căutare
Sponsor
Categorii
Citeste mai mult
Networking
Magneto Resistive RAM Market will reach at a CAGR of 62.1% from to 2030
The global magneto resistive RAM (MRAM) market size is USD 270.1 million in 2021,...
By vipinmsg 2024-01-30 12:04:18 0 4K
Alte
Umrah Packages London with Cheapest UK Deals
Umrah is a sacred adventure that holds deep meaning for Muslims across the globe. For the ones...
By hajjumrah4u 2025-07-01 10:44:24 0 2K
Networking
Cables and Leads for Medical Equipment Market Understanding Global Trends, Growth, Size, Segmentation, and Opportunities: Forecast by Fact MR
The global market for cables and leads used in medical equipment is experiencing...
By akshaygorde 2025-05-06 13:31:22 0 2K
Alte
AI-Powered Succession Planning: Preparing Future-Ready Leaders
In today’s fast-changing business environment, leadership gaps can directly affect...
By thomas456 2025-09-12 11:59:32 0 494
Shopping
Nickel Alloy Market Share: Growth, Value, Size, Scope, and Analysis
"Executive Summary Nickel Alloy Market : The global nickel alloy market size was...
By mikewarn00 2025-07-21 06:59:03 0 1K
Sponsor
TikTikTalk https://tiktiktalk.com